|
|
Karolinska Institutet, StockholmKarolinska Institutet is the coordinator of the project and has major experience from coordinating large networks and consortia in biomedicine. The input from the president, Professor Harriet Wallberg-Henriksson, in the development of a management structure for the consortium as well as part of the dissemination structure for commercialisation will be invaluable. The partner contributes with several research groups active in different parts of the project.
Prof Lars Klareskog has a background in basic immunology, and was responsible for the original description of MHC class II dependent T cell activation as a pathogenetic principle in RA, and was also active in the development of the collagen arthritis and simple adjuvant arthritis rodent disease models, and was chair of clinical immunology (Uppsala University, Sweden) before being appointed professor and chairman of Rheumatology at Karolinska (1993). After that the rheumatology unit at Karolinska has contributed to all most major clinical trials of currently used biologics. The unit has also established a unit for translational research in rheumatology, currently involving about 40 persons (senior scientists, postdocs, clinicians/scientists, PhD students, research nurses and technicians). Among other commitments, he is member of the Nobel Assembly since 1995 and has also been member of the Nobel Committee and served as the president of the European Rheumatology Congress in 2002.
Prof Ingrid Lundberg is clinician/scientist, and has create a research group devoted to translational science in myositis, and has led European study groups in myositis, and is currently chairperson of a EULAR/ACR group committed to the creation of new international classification criteria for myositis. Prof Ulf Andersson is chairman of pediatric rheumatology at Karolinska Institutet/Karolinska University Hospital, and has created a research unit focusing on both translational research in pediatric rheumatology and on molecular and clinical studies on the key proinflammatory molecule HMGB1. Prof. Mats G Hansson will contribute international expertise within the field of bioethics and legal issues. He is presently conducting a large international programme within the field of ethics related to bio banks as well as clinical trials and related issues. Research is being carried out in close collaboration with stakeholders such as patient organisations and political representatives.
Dr Gisela Kobelt will provide international expertise within the field of health economics. She has an extensive experience of health economics work from both many years in industry and subsequently from academic work at Karolinska Institutet.
Contact
|
